Abstract:tity still remains unanswered. All three entities share a common immunophenotype and some cytogenetic abnormalities, such as whole or partial gains of chromosomes 3, 12 and 18. However, certain differences indicate that NMZL differs biologically from SMZL and MALT lymphomas: the MALT-specific translocations and the SMZL-associated deletion of 7q are characteristically absent. Regarding the cell of origin, the normal counterpart of NMZL is considered an antigen-experienced, postgerminal center memory B cell that has not necessarily undergone germinal center transit. Findings from gene expression profiling studies point to a genetic similarity between NMZL and MALT lymphomas. However, nuclear factor-κB activation is less frequently encountered compared to MALT lymphomas [1, 2] . A third issue of interest is the invariable presence of scattered large cells (immunoor centroblasts) which may comprise >20% of the neoplastic cell population in up to half of all cases, in contrast to other low-grade B cell lymphomas. The importance of large cells has been a major debate between pathologists that has not been completely resolved even today. A threshold of >20 or >50% of large cells has been used as a cut-off for defining ‘transformed lymphoma’. Recently, in 2011, a consensus was reached to use the term ‘transformed NMZL’ only if Nodal marginal zone lymphoma (NMZL) is a very rare lymphoma subtype comprising less than 2% of all nonHodgkin lymphomas. It is one of the three well-recognized entities within the broad category of marginal zone lymphomas (MZL), together with splenic marginal zone (SMZL) and mucosa-associated lymphoid tissue (MALT) lymphomas [1] . There are several aspects of interest and unresolved issues regarding this relatively new entity. The first point of interest in NMZL is its diagnostic difficulty. Although NMZL is a separate entity, its recognition is rather challenging, at least at the histopathological level due to a lack of specific markers. Thus, the diagnosis of NMZL relies on clinical presentation in conjunction with a compatible histology/immunophenotype and requires lymph node involvement with concurrent absence of splenic and extranodal disease. Still, there are cases that are difficult to classify with certainty, such as disseminated disease at the time of diagnosis, cases with extranodal involvement and nonregional lymph nodes, or cases with prominent splenomegaly as the major finding combined with extensive abdominal or widespread lymphadenopathy and/or MALT-site involvement. A second point of interest focuses on the biologic similarity of NMZL to the other two entities of MZL. The question of whether NMZL truly represents a distinct enReceived: June 11, 2014 Accepted: June 28, 2014 Published online: November 4, 2014

Synthesis and characterization of molecularly imprinted polymer microspheres functionalized with POSS

Preparation of Capsaicin Molecular Imprinting Polymers and Application to Solid Phase Extraction

The Preparation and Characterization of PMMA/POSS-OH Hybrid Fiber

Study on P-Hydroxybenzoic Acid Imprinted Polymers with Different Functional Monomers and Their Molecular Recognition Characteristics

Transformed Nodal Marginal Zone Lymphoma versus Diffuse Large B Cell Lymphoma: The MicroRNA Aspect

Investigating two distinct dummy templates molecularly imprinted polymers as paclitaxel adsorbent in synthesis system and releaser in biological samples

PREPARATION OF MOLECULARLY IMPRINTED POLYMERS AND STUDIES ON THEIR PORE-STRUCTURE

Poly(ether-ester Anhydride)-Based Amphiphilic Block Copolymer Nanoparticle As Delivery Devices for Paclitaxel

Selective separation and inexpensive purification of paclitaxel based on molecularly imprinted polymers modified with ternary deep eutectic solvents

Screening of functional monomers and solvents for the molecular imprinting of paclitaxel separation: a theoretical study

A modified microfluidic chip for fabrication of paclitaxel-loaded poly(l-lactic acid) microspheres

PREPARATION AND AFFINITY ASSESSMENT OF MONOCROTOPHOS MOLECULARLY IMPRINTED POLYMERS

Blends of Paclitaxel with POSS-Based Biodegradable Polyurethanes: Morphology, Miscibility, and Specific Interactions

Pharmacokinetics and Biodistribution of Polymeric Micelles of Paclitaxel with Pluronic P123

Characterization and Quality Assessment of Binding Properties of the Monocrotophos Molecularly Imprinted Microspheres Prepared by Precipitation Polymerization in Toluene

Synthesis of Magnetic Molecularly Imprinted Polymer Particles for Selective Adsorption and Separation of Dibenzothiophene

Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles.

Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles

Molecularly imprinted polymeric microspheres with metalloporphyrin-based molecular recognition sites coassembled with methacrylic acid

Development and Characterization of Paclitaxel-Loaded Li-pid-Coated Mesoporous Silica Nanoparticles for Ph-Responsive Tumor-Targeted Drug Delivery

Successfully Tailoring the Pore Size of Mesoporous Silica Nanoparticles: Exploitation of Delivery Systems for Poorly Water-Soluble Drugs.